Navigation Links
AuraSense Therapeutics Secures Series B Equity Investment
Date:12/22/2011

EVANSTON, Ill., Dec. 22, 2011 /PRNewswire/ -- AuraSense Therapeutics, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation- and chemo-therapeutics for a variety of diseases, including applications in oncology, dermatology, neurology, and for cardiovascular disorders, has closed its Series B financing.  Investors included Abbott Biotech Ventures, a subsidiary of Abbott.  Other key individual investors included Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina; Eric Schmidt, Executive Chairman of Google; and Craig Mundie, Chief Research and Strategy Officer of Microsoft.  Terms of the investment were not disclosed.

"We are delighted to complete this financing and have this consortium of investors join us in our mission to transform the field of gene regulation," said Chad Mirkin, co-founder of AuraSense Therapeutics.  "This financing underscores the highly unique benefits of the SNA platform and will accelerate our efforts to develop it to its full potential – supporting therapies for multiple diseases."

Schiff Hardin LLP served as deal counsel to AuraSense Therapeutics for the investment transaction.

About AuraSense Therapeutics, LLC

AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton at Northwestern University.  The Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates.  Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases.  The Company's SNA technology overcomes the most difficult obstacles to gene regulation:  genetic targeting with safe and effective in vivo performance.  For additional information about the company, please visit www.aurasensetherapeutics.com.


'/>"/>
SOURCE AuraSense Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... March 28, 2017 The global ... USD 8.0 billion by 2025, according to a new ... of infectious diseases and cancer is expected to upsurge ... diagnosis over the coming years. In addition, higher number ... and allogenic stem cell therapy, due to adverse effects ...
(Date:3/27/2017)... Summary This report provides all the ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
(Date:3/27/2017)... WI (PRWEB) , ... March 27, 2017 , ... ... new patients for custom smile makeovers without requiring a referral. Trimble ... orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Drs. Justin ... Awareness Week by teaching their patients about the key role this treatment plays in ... from an experienced endodontist. To better serve those who need a root canal in ...
(Date:3/27/2017)... Arlington, VA (PRWEB) , ... March 27, 2017 ... ... version 3.0 was transitioned to the OSEHRA popHealth Community in 2014. ... Steering Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member ...
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
Breaking Medicine News(10 mins):